Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.
HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...
BOSTON--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for cancer and autoimmune diseases, today announced it ...
Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The ...
Surface model of SpCas9–reverse transcriptase–pegRNA–target DNA complex. The prime editor, composed of a SpCas9 and a reverse transcriptase, reverse transcribes template sequence in pegRNA, resulting ...
After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...
A case report published in the New England Journal of Medicine describes a previously unidentified orthonairovirus, dubbed Wetland virus (WELV), in a man bitten by a tick at a wetland park in Inner ...
REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results